Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Intensive care medicine rapid practice guidelines (ICM-RPG): paving the road of the future

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Focus on fluid therapy in critically ill patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Focus on sepsis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Liberal versus restrictive fluid therapy in critically ill patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Conservative vs liberal fluid therapy in septic shock (CLASSIC) trial—Protocol and statistical analysis plan

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Consensus on technical procedures for simulation-based training in anaesthesiology: A Delphi-based general needs assessment

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Prediction of bleeding by thromboelastography in ICU patients with haematological malignancy and severe sepsis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Elie Azoulay
  • Philippe R Bauer
  • Eric Mariotte
  • Lene Russell
  • Paul Knoebl
  • Ignacio Martin-Loeches
  • Frédéric Pène
  • Kathryn Puxty
  • Pedro Povoa
  • Andreas Barratt-Due
  • Jose Garnacho-Montero
  • Julia Wendon
  • Laveena Munshi
  • Dominique Benoit
  • Michael von Bergwelt-Baildon
  • Marco Maggiorini
  • Paul Coppo
  • Spero Cataland
  • Agnès Veyradier
  • Andry Van de Louw
  • Nine-i Investigators
Vis graf over relationer

Thrombotic thrombocytopenic purpura (TTP) is fatal in 90% of patients if left untreated and must be diagnosed early to optimize patient outcomes. However, the very low incidence of TTP is an obstacle to the development of evidence-based clinical practice recommendations, and the very wide variability in survival rates across centers may be partly ascribable to differences in management strategies due to insufficient guidance. We therefore developed an expert statement to provide trustworthy guidance about the management of critically ill patients with TTP. As strong evidence was difficult to find in the literature, consensus building among experts could not be reported for most of the items. This expert statement is timely given the recent advances in the treatment of TTP, such as the use of rituximab and of the recently licensed drug caplacizumab, whose benefits will be maximized if the other components of the management strategy follow a standardized pattern. Finally, unanswered questions are identified as topics of future research on TTP.

OriginalsprogEngelsk
TidsskriftIntensive Care Medicine
Vol/bind45
Udgave nummer11
Sider (fra-til)1518-1539
ISSN0342-4642
DOI
StatusUdgivet - nov. 2019

ID: 58576020